LZLi Zhou

Li Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Li Zhou has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Aiqun Shi

    Department of Rehabilitation Medicine , Jinhua Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University , Jinhua , China

    1 shared publication
  • Chengjiang Liu

    Department of Painology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Fangping Bao

    Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China

    1 shared publication
  • Honggang Zhang

    Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China

    1 shared publication
  • Jiasheng Wang

    Department of Rehabilitation Medicine , Jinhua Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University , Jinhua , China

    1 shared publication
  • Jun Li

    Department of Anesthesiology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang Province, 310022, People’s Republic of China

    1 shared publication

Latest Publications

  • Construction and Preliminary Validation of the Chinese Assessment Scale for Zoster-associated Pain Based on the Delphi Method

    by Zheng Siyao, Chengjiang Liu, Liang Yifu, Li Yunze, Zhou Li, Feng Zhiying

    This study aimed to develop and preliminarily validate a Chinese assessment scale for zoster-associated pain (ZAP) based on the Delphi method. A descriptive study was conducted. An initial item pool was developed based on domestic and international guidelines, expert consensus, and professional discussions related to ZAP. The Delphi method was employed in September 2023 to screen and revise the items, forming a preliminary version of the scale. From October 5, 2023, to January 31, 2024, a total of 209 patients with ZAP treated at the Department of Pain Management, The First Affiliated Hospital of Zhejiang University School of Medicine, were surveyed using this scale. Items were excluded using several criteria: standard deviation < 0.7 or coefficient of variation < 0.15 (dispersion trend method), correlation coefficient < 0.2 or non-significant differences (P > 0.05) (correlation analysis), non-significant differences (P > 0.05) (critical ratio method), and factor loadings < 0.4 or cross-loadings > 0.4 on multiple factors (exploratory factor analysis). Reliability was evaluated using internal consistency (Cronbach’s α), and validity was assessed through content and construct validity. Two rounds of Delphi expert consultation were conducted, involving 15 clinical pain specialists. A preliminary 16-item scale was developed based on threshold screening criteria. The response rate for both Delphi rounds was 100%, and the authority coefficients of experts were all > 0.7. Cronbach's α coefficients were 0.847 and 0.909 for the first and second rounds, respectively. Kendall’s W coefficients were 0.259 (χ² = 108.814, P < 0.001) and 0.291 (χ² = 74.130, P < 0.001) across the two rounds. Following item analysis of the 209 patient responses, 15 items were retained. The content validity of the scale was judged to be satisfactory by pain specialists. After further validity testing, 11 items were finally retained. The Kaiser-Meyer-Olkin (KMO) value was 0.837, and Bartlett’s test of sphericity was significant (P < 0.001). Exploratory factor analysis extracted three common factors, accounting for a cumulative variance contribution of 64.791%. The final Cronbach’s α coefficient was 0.808. The developed Chinese version of the ZAP assessment scale consists of 11 items across three dimensions, demonstrating good reliability, validity, and applicability.

  • Open Access

    Combining Pulsed Radiofrequency With Transcranial Magnetic Stimulation to Manage Hemiplegic Shoulder Pain and Somatosensory Nerve Transmissions

    by Ying Zhao, Xuehan Zang, Lingyan Wang, Zhengmei Yan, Jun Yang, Qingchuan Gu, Li Zhou, Xianwei Che, Aiqun Shi, Jiasheng Wang

    Background: Hemiplegic shoulder pain (HSP) is a major cause of disability that is still challenging to manage in clinical practices. Both pulsed radiofrequency (PRF) and repetitive transcranial magnetic stimulation (rTMS) could reduce poststroke HSP to certain extents. However, it remains unknown whether combined PRF and rTMS treatment could increase analgesic efficacy for poststroke HSP. Objectives: To evaluate the therapeutic efficacy of combined PRF and transcranial magnetic stimulation in treating HSP. Study Design: This was a randomized, assessor‐blinded pilot study. Setting: The rehabilitation department of a single hospital. Methods: In this pilot study, a 3‐arm study design was utilized to compare the treatment efficacy of combined PRF and rTMS treatment with a single PRF or rTMS strategy. Patients were randomly assigned to receive PRF, rTMS, or combined treatment. Outcomes assessments included pain intensity, motor activity, and neurophysiological activities. Results: Our data indicated that rTMS acted more efficiently to reduce pain than PRF treatment. Combined treatment had a larger long‐term efficacy than rTMS treatment alone. Both combined and single treatment improved motor recovery and neural transmissions, such as suprascapular nerve amplitude and somatosensory N20. Limitations: As we designed a pilot study, the sample size was small in each treatment arm. Our findings thus need to be validated in future large studies. Conclusion(s): These novel findings provide a safe and effective treatment strategy for poststroke HSP by combining PRF with rTMS treatment. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2500100181

  • Open Access

    Oxycodone vs the Combination of Fentanyl and Remifentanil for General Anesthesia in Laparoscopic Uterine Myomas Surgery: A Prospective, Randomized, Controlled Study

    by Xiaowei Xu, Honggang Zhang, Jun Li, Li Zhou, Shengmei Zhu, Fangping Bao

    Purpose: This study evaluated whether oxycodone alone could substitute for fentanyl combined with remifentanil for general anesthesia in laparoscopic uterine myoma surgery. Patients and Methods: 90 adult female patients were randomized into three groups: oxycodone 0.35 mg/kg (Group A), oxycodone 0.30 mg/kg (Group B), or fentanyl 5 μg/kg (Group C) for induction. Anesthesia was maintained with propofol plus saline (Groups A/B) or remifentanil (Group C). Primary outcomes included Numerical Rating Scale (NRS) pain scores in the Post-Anesthesia Care Unit (PACU). Secondary outcomes were intubation reaction, vital signs, extubation/PACU times, Ramsey Sedation Scores (RSS) in PACU, NRS pain scores and adverse events within 48 hours postoperatively. Results: Intubation reactions were rare (one case each in Groups B/C, none in Group A). Group B had significantly lower PACU NRS scores than Group C (0.6 ± 0.7 vs 1.3 ± 1.4, P = 0.011), while Group A showed a nonsignificant trend (0.8 ± 0.9 vs 1.3 ± 1.4, P = 0.051). RSS scores, extubation/PACU times, and 48-hour NRS scores were comparable. However, oxycodone groups had longer postoperative evacuation times than fentanyl group (Group A vs Group C: 20.0 ± 7.3 hours vs 16.5 ± 5.1 hours, P=0.038; Group B vs Group C: 20.3 ± 8.2 hours vs 16.5 ± 5.1 hours, P=0.034). Conclusion: Oxycodone alone provides superior early postoperative analgesia compared to fentanyl-remifentanil in laparoscopic myoma surgery but may delay bowel recovery.